TAT and HIV-1 infection: Overall, our screening identified novel 1,3,4-oxadiazole compounds that inhibited HIV-1 Tat, and subsequent SAR-based optimization led to the derivatives <b>9</b> and <b>13</b> development that could be a promising scaffold for developing a new class of therapeutic agents for HIV-1 infection.